CRVS
Price
$3.34
Change
+$0.14 (+4.38%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
228.37M
Earnings call today
IMMP
Price
$1.86
Change
-$0.07 (-3.63%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
293.56M
20 days until earnings call
Ad is loading...

CRVS vs IMMP

Header iconCRVS vs IMMP Comparison
Open Charts CRVS vs IMMPBanner chart's image
Corvus Pharmaceuticals
Price$3.34
Change+$0.14 (+4.38%)
Volume$79.91K
Capitalization228.37M
Immutep
Price$1.86
Change-$0.07 (-3.63%)
Volume$300
Capitalization293.56M
CRVS vs IMMP Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. IMMP commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and IMMP is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (CRVS: $3.35 vs. IMMP: $1.86)
Brand notoriety: CRVS and IMMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 530% vs. IMMP: 104%
Market capitalization -- CRVS: $228.37M vs. IMMP: $293.56M
CRVS [@Biotechnology] is valued at $228.37M. IMMP’s [@Biotechnology] market capitalization is $293.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileIMMP’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • IMMP’s FA Score: 0 green, 5 red.
According to our system of comparison, IMMP is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while IMMP’s TA Score has 6 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 4 bearish.
  • IMMP’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IMMP is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а -4.83% price change this week, while IMMP (@Biotechnology) price change was +11.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

IMMP is expected to report earnings on Aug 27, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMMP($294M) has a higher market cap than CRVS($228M). IMMP YTD gains are higher at: -11.060 vs. CRVS (-40.187). CRVS has higher annual earnings (EBITDA): -25M vs. IMMP (-43.83M). IMMP has more cash in the bank: 159M vs. CRVS (41.7M). CRVS has less debt than IMMP: CRVS (354K) vs IMMP (1.69M). CRVS (0) and IMMP (0) have equivalent revenues.
CRVSIMMPCRVS / IMMP
Capitalization228M294M78%
EBITDA-25M-43.83M57%
Gain YTD-40.187-11.060363%
P/E RatioN/AN/A-
Revenue00-
Total Cash41.7M159M26%
Total Debt354K1.69M21%
FUNDAMENTALS RATINGS
CRVS vs IMMP: Fundamental Ratings
CRVS
IMMP
OUTLOOK RATING
1..100
7030
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
8573
SMR RATING
1..100
9792
PRICE GROWTH RATING
1..100
5842
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRVS's Valuation (71) in the Pharmaceuticals Major industry is in the same range as IMMP (84) in the Biotechnology industry. This means that CRVS’s stock grew similarly to IMMP’s over the last 12 months.

IMMP's Profit vs Risk Rating (73) in the Biotechnology industry is in the same range as CRVS (85) in the Pharmaceuticals Major industry. This means that IMMP’s stock grew similarly to CRVS’s over the last 12 months.

IMMP's SMR Rating (92) in the Biotechnology industry is in the same range as CRVS (97) in the Pharmaceuticals Major industry. This means that IMMP’s stock grew similarly to CRVS’s over the last 12 months.

IMMP's Price Growth Rating (42) in the Biotechnology industry is in the same range as CRVS (58) in the Pharmaceuticals Major industry. This means that IMMP’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as IMMP (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to IMMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSIMMP
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Ad is loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EIVIX13.51N/A
N/A
Allspring Special Large Cap Value Inst
VSTIX55.32N/A
N/A
VALIC Company I Stock Index
HNMDX12.91N/A
N/A
Heartland Mid Cap Value Institutional
DLACX13.97N/A
N/A
BNY Mellon Large Cap Equity Y
BRZIX12.47-0.04
-0.32%
BlackRock Sus Adg Intl Eq Ins

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-4.48%
SYRE - CRVS
36%
Loosely correlated
+1.60%
VRDN - CRVS
35%
Loosely correlated
+2.16%
VKTX - CRVS
35%
Loosely correlated
+2.04%
ACRV - CRVS
34%
Loosely correlated
-7.52%
FULC - CRVS
34%
Loosely correlated
-5.23%
More

IMMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMMP has been loosely correlated with PRRUF. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IMMP jumps, then PRRUF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMMP
1D Price
Change %
IMMP100%
-4.93%
PRRUF - IMMP
43%
Loosely correlated
N/A
CALC - IMMP
38%
Loosely correlated
+0.50%
ARCT - IMMP
31%
Poorly correlated
-2.58%
AXON - IMMP
31%
Poorly correlated
+0.02%
SNPX - IMMP
30%
Poorly correlated
-3.09%
More